AirDuo Digihaler (salmeterol/fluticasone proprionate) / Teva - LARVOL DELTA

Teva Asthma Predictive Analytics Study (clinicaltrials.gov) - P4 | N=101 | Completed | Sponsor: University of Michigan | Trial primary completion date: Sep 2024 ➔ Dec 2023 | Active, not recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Dec 2023

Heterogeneity • Trial completion • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Teva Asthma Predictive Analytics Study (clinicaltrials.gov) - P4 | N=101 | Active, not recruiting | Sponsor: University of Michigan | Trial completion date: Jul 2023 ➔ Sep 2024 | Trial primary completion date: Jul 2023 ➔ Sep 2024

Heterogeneity • Trial completion date • Trial primary completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Teva Asthma Predictive Analytics Study (clinicaltrials.gov) - P4 | N=101 | Active, not recruiting | Sponsor: University of Michigan | Recruiting ➔ Active, not recruiting

Enrollment closed • Heterogeneity • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Teva to Present New Data from CONNECT2 Study on its Digihaler System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting (Businesswire) - "Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd...announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the CONNECT2 clinical trial program as well as information on patients and healthcare professionals' real-world use of the smart inhaler system. The Digihaler System is the first and only smart inhaler system with built-in sensors that provide objective inhaler event data to help patients and their doctors support asthma management and develop personalized treatment plans."

P4 data • Retrospective data • Asthma • Respiratory Diseases

Teva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting (Businesswire) - "Teva Pharmaceuticals...today announced that new findings from the CONNECT clinical trial program assessing the use of the Digihaler System compared to standard of care (SoC) in asthma management will be presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific meeting, being held November 10-14 in Louisville, Kentucky. The data will be featured in six posters, three of which will highlight results from the CONNECT1 clinical trial evaluating the ProAir® Digihaler (albuterol sulfate) inhalation powder with a built-in electronic sensor in asthma management versus SoC. Three additional posters will share the first data from the CONNECT2 clinical trial assessing the joint use of the ProAir Digihaler and the AirDuo® Digihaler (fluticasone propionate and salmeterol) inhalation powder with a built-in sensor in asthma management versus SoC."

P4 data • Asthma • Respiratory Diseases

Teva Asthma Predictive Analytics Study (clinicaltrials.gov) - P4; N=100; Recruiting; Sponsor: University of Michigan

New P4 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

"@TevaUSA announced that it launched its AirDuo Digihaler and ArmonAir Digihaler #digitalinhalers in the U.S. https://t.co/k4pvIz8ZkE" (@DeviceTalks)

"#TevaRespiratory, an affiliate of @TevaUSA, completed its #digitalinhaler portfolio today with the launch of two new products: #AirDuoDigihaler and #ArmonAirDigihaler. #Digihaler records inhaler-use data every time the cap is opened or a user inhales. #respiratory #inhaler" (@Mr_C_Wadd)

Teva Launches Two Digital Inhalers in the U.S., AirDuo Digihaler (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir Digihaler (fluticasone propionate) Inhalation Powder (Businesswire) - "Teva... today announced the launch of AirDuo® Digihaler® (fluticasone propionate and salmeterol) inhalation powder and ArmonAir® Digihaler® (fluticasone propionate) inhalation powder, two digital maintenance inhalers for patients with asthma. AirDuo® Digihaler® is a prescription medicine used to control symptoms of asthma and to prevent symptoms such as wheezing in people 12 years of age and older. ArmonAir® Digihaler® is a prescription medicine for the long-term treatment of asthma in patients 12 years and older. "

Launch US • Asthma • Respiratory Diseases